CompletedPhase 2NCT04907682
Pharmacokinetics, Tolerability and Safety of Favipiravir Compared to Ribavirin for the Treatment of Lassa Fever
Studying Lassa fever
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Bernhard Nocht Institute for Tropical Medicine
- Principal Investigator
- Peter Akhideno, DrISTH
- Intervention
- Ribavirin iv(drug)
- Enrollment
- 40 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2022
Study locations (2)
- Irrua Specialist Teaching Hospital, Irrua, Edo, Nigeria
- Federal Medical Center of Owo, Owo, Ondo State, Nigeria
Collaborators
University of Hamburg-Eppendorf · Alliance for International Medical Action · Institut National de la Santé Et de la Recherche Médicale, France · University of Bordeaux · Federal Medical Centre, Owo · Irrua Specialist Teaching Hospital
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04907682 on ClinicalTrials.govOther trials for Lassa fever
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07419373ARN-75039 Lassa Fever Treatment in West AfricaArisan Therapeutics, Inc.
- RECRUITINGPHASE2, PHASE3NCT06212336ISTH/ANRS 0409s INTEGRATE Lassa Fever StudyIrrua Specialist Teaching Hospital
- ACTIVE NOT RECRUITINGPHASE1NCT06546709DMID 23-0015; Lassa Fever CVD 1000Wilbur Chen, MD, MS
- RECRUITINGPHASE2NCT05868733A Lassa Fever Vaccine Trial in Adults and Children Residing in West AfricaInternational AIDS Vaccine Initiative
- RECRUITINGPHASE2NCT06222723LAssa Fever Adjunct Treatment With DEXamethasoneBernhard Nocht Institute for Tropical Medicine
- ACTIVE NOT RECRUITINGNCT03655561Lassa Fever Clinical Course and Prognostic Factors in NigeriaAlliance for International Medical Action